Edward Pratt

1.2k total citations · 4 hit papers
24 papers, 703 citations indexed

About

Edward Pratt is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Edward Pratt has authored 24 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Edward Pratt's work include Diabetes Treatment and Management (15 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (6 papers). Edward Pratt is often cited by papers focused on Diabetes Treatment and Management (15 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (6 papers). Edward Pratt collaborates with scholars based in United States, Germany and Singapore. Edward Pratt's co-authors include Axel Haupt, Kieren J. Mather, Xiaosu Ma, Deborah A. Robins, Christof Kazda, Маниге Кониг, Lisa Connery, Tamer Coşkun, Sean Wharton and Rong Liu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Edward Pratt

18 papers receiving 686 citations

Hit Papers

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults... 2023 2026 2024 2025 2023 2023 2023 2025 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
    2023 259 citations Sean Wharton, Thomas Blevins et al. New England Journal of Medicine profile →
  2. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
    2023 120 citations Tim Heise, J. Hans DeVries et al. Diabetes Care profile →
  3. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
    2023 97 citations Juan P. Frías, Stanley H. Hsia et al. The Lancet profile →
  4. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
    2025 18 citations Éric Ravussin, Guillermo Sánchez‐Delgado et al. Cell Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward Pratt United States 11 516 272 200 164 144 24 703
Tamer Coskun United States 3 566 1.1× 356 1.3× 292 1.5× 194 1.2× 157 1.1× 6 787
Sirel Gurbuz United States 5 677 1.3× 430 1.6× 341 1.7× 235 1.4× 192 1.3× 7 921
Federico C. Pérez Manghi United Kingdom 3 877 1.7× 375 1.4× 283 1.4× 383 2.3× 291 2.0× 3 1.1k
Brandon K. Bergman United States 5 924 1.8× 393 1.4× 299 1.5× 397 2.4× 297 2.1× 12 1.2k
Christof Kazda United States 13 836 1.6× 234 0.9× 175 0.9× 290 1.8× 411 2.9× 30 1.0k
Trine Vang Skjøth Denmark 12 1.1k 2.2× 614 2.3× 304 1.5× 384 2.3× 344 2.4× 23 1.3k
Scheen Aj Belgium 8 296 0.6× 162 0.6× 133 0.7× 100 0.6× 102 0.7× 57 578
Renato O. Crajoinas Brazil 11 471 0.9× 66 0.2× 97 0.5× 265 1.6× 181 1.3× 24 719
Thalia Panagiotopoulou Greece 3 270 0.5× 105 0.4× 73 0.4× 100 0.6× 92 0.6× 3 373
J Lüdemann United States 6 589 1.1× 177 0.7× 76 0.4× 388 2.4× 146 1.0× 12 673

Countries citing papers authored by Edward Pratt

Since Specialization
Citations

This map shows the geographic impact of Edward Pratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Pratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Pratt more than expected).

Fields of papers citing papers by Edward Pratt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Pratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Pratt. The network helps show where Edward Pratt may publish in the future.

Co-authorship network of co-authors of Edward Pratt

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Pratt. A scholar is included among the top collaborators of Edward Pratt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Pratt. Edward Pratt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qu, Hongchang, et al.. (2026). Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obesity and Metabolism. 28(4). 2651–2660.
2.
Martin, Corby K., Owen Carmichael, Susan Carnell, et al.. (2025). Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine. 31(9). 3141–3150. 6 indexed citations
3.
Ravussin, Éric, Guillermo Sánchez‐Delgado, Corby K. Martin, et al.. (2025). Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metabolism. 37(5). 1060–1074.e4. 18 indexed citations breakdown →
4.
Pieber, Thomas R., Shweta Urva, Axel Haupt, et al.. (2025). Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide. Frontiers in Endocrinology. 16. 1627947–1627947.
5.
Briere, Daniel A., Hongchang Qu, Katherine Lansu, et al.. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 102. 102271–102271. 4 indexed citations
6.
Pratt, Edward, Filip K. Knop, Shweta Urva, et al.. (2024). A Long-Acting Glucose Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss Without Nausea or Vomiting. Diabetologie und Stoffwechsel. 19(S 01). S77–S77.
7.
Knop, Filip K., Shweta Urva, Mallikarjuna Rettiganti, et al.. (2024). A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy. Diabetologie und Stoffwechsel. 19(S 01). S73–S73. 3 indexed citations
8.
Mather, Kieren J., Andrea Mari, Tim Heise, et al.. (2024). Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. The Journal of Clinical Endocrinology & Metabolism. 109(12). 3046–3054. 12 indexed citations
9.
10.
11.
12.
13.
Frías, Juan P., Stanley H. Hsia, Rong Liu, et al.. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. The Lancet. 402(10400). 472–483. 97 indexed citations breakdown →
14.
Wharton, Sean, Thomas Blevins, Lisa Connery, et al.. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 389(10). 877–888. 259 indexed citations breakdown →
15.
Heise, Tim, J. Hans DeVries, Jing Li, et al.. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 46(5). 998–1004. 120 indexed citations breakdown →
16.
Martin, Corby K., Éric Ravussin, Guillermo Sánchez‐Delgado, et al.. (2023). THE EFFECT OF TIRZEPATIDE DURING WEIGHT LOSS ON FOOD INTAKE, APPETITE, FOOD PREFERENCE AND FOOD CRAVING IN PEOPLE WITH OBESITY. Canadian Journal of Cardiology. 39(10). S239–S239. 1 indexed citations
17.
Garhyan, Parag, Edward Pratt, Oliver Klein, et al.. (2022). Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. Journal of Diabetes Science and Technology. 17(2). 274–282.
18.
Pratt, Edward, et al.. (2014). PO423 SINGLE-DOSE PHARMACOKINETICS AND GLUCODYNAMICS OF THE NOVEL, LONG-ACTING BASAL INSULIN LY2605541 IN HEALTHY SUBJECTS. Diabetes Research and Clinical Practice. 106. S261–S261.
19.
Pratt, Edward, et al.. (2011). Phaeochromocytoma Mimicking Scleroderma. International Journal of Endocrinology. 2011. 1–2. 1 indexed citations
20.
Flanagan, Daniel, et al.. (2002). Alcohol consumption alters insulin secretion and cardiac autonomic activity. European Journal of Clinical Investigation. 32(3). 187–192. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamer Coskun Breakdown of academic impact, for papers by Sirel Gurbuz Breakdown of academic impact, for papers by Federico C. Pérez Manghi Breakdown of academic impact, for papers by Brandon K. Bergman Breakdown of academic impact, for papers by Christof Kazda Breakdown of academic impact, for papers by Trine Vang Skjøth Breakdown of academic impact, for papers by Scheen Aj Breakdown of academic impact, for papers by Renato O. Crajoinas Breakdown of academic impact, for papers by Thalia Panagiotopoulou Breakdown of academic impact, for papers by J Lüdemann
Rankless by CCL
2026